Pharma Deals With The DOJ
Executive Summary
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
You may also be interested in...
Dr. Reddy's Defeat Of FCA Case Offers 'Guidepost' For Litigation After Escobar
Dismissal of False Claims Act suit against Dr. Reddy's shows impact of US Supreme Court's Escobar decision. Government FCA pharma recoveries shot up 58% from 2015 to 2016; graphic breaks out settlements by kickback, off-label promotion and improper billing cases.
US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others
As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.
Insulin Pricing, PBM Relationships Under Government Microscope
Minnesota Attorney General demands Novo Nordisk and Sanofi provide information on their insulin pricing; they are also among several companies facing probes over their contracts with pharmacy benefit managers.